Project Grant 1520463

This SBIR Phase I award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $273,550 to Biocognon LLC for the development of a combinatorial platform to discover improved molecular recognition components for use in therapeutic and diagnostic antibodies. The project aims to utilize synthetic biology, next-generation DNA sequencing, and computational biology to efficiently generate and screen libraries of antibody...

This SBIR Phase I project, awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), aims to develop a method to turn on cancer immunotherapies only at the site of disease. The $275,000 award will support Synsorybio, Inc., a for-profit organization, in creating protein switches that activate immunotherapies in response to disease signals, rather than indiscriminately throughout the body. This approach seeks to improve the...

This $274,975 Small Business Innovation Research (SBIR) Phase I grant awarded by the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) supports the development of an antibody therapy targeting neoantigens in acute myeloid leukemia (AML). The project aims to create a platform technology that combines cancer-specific antibodies and adoptive natural killer (NK) immune cells to achieve high efficacy and low toxicity in treating relapsed/refractory AML. Key...

This National Science Foundation Project Grant of $255,927 awarded to Invvax, Inc. on March 1, 2022 seeks to develop stable prophylactic antibodies through February 2023. Funded through the NSF Engineering Directorate's CFDA 47.041 program, this Small Business Innovation Research Phase I project will engineer mutations to antibody Fc regions to resist degradation and enhance binding to the neonatal Fc receptor for potentially decades-long duration. Specifically, the awardee will combine known...

Grant Award Summary Acpharis received a $202,467 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) for the period September 1, 2025, through August 31, 2026. The award supports the development of commercial-quality software for predicting antibody-antigen complex structures with significantly improved accuracy over existing computational methods. The software integrates machine learning with...

This SBIR Phase I award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $275,000 to Caravel Bio, Inc. to develop a novel synthetic biology platform for high-throughput directed evolution of spore-displayed enzymes. The project aims to create customizable enzyme solutions for industrial biocatalyst applications by improving key properties like enzyme activity, stability, and loading density. The technology uses a...

Federal Project Grant Award Summary Nano-Beads Protein Innovations, Inc. received a $620,174 Project Grant award dated September 1, 2025, from the National Institute of Biomedical Imaging and Bioengineering under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The award supports development of NANO-AB, an innovative nanoscale biomaterial designed to advance monoclonal antibody (mAb) purification technologies. The project,...

This $275,000 Small Business Innovation Research (SBIR) Phase I award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program supports the development of a label-free, high-resolution, high-throughput protein screening platform called Vibrational Spectroscopy with Metasurface Optics (VISMO). The technology aims to enable simultaneous, minute-scale measurement of millions of protein samples, which would dramatically improve the lengthy and costly cycles...

This $274,797 National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award to Deepseq.ai LLC supports the development of an AI-driven platform to accelerate the identification of highly developable single-domain antibodies for drug discovery. The proposed work aims to create a multimodal AI model capable of rapidly screening large libraries to generate lead molecules with favorable binding affinity, stability, and manufacturability. This project...

This $2 million cooperative agreement from the National Science Foundation will support Protabit LLC in developing artificial intelligence-enabled antibody engineering approaches to generate neutralizing antibodies against SARS-CoV-2. Funded through Jul 2022 to Jun 2024 under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084), the project aims to discover a large array of high-affinity neutralizing antibodies targeting multiple regions of the SARS-CoV-2 spike protein. This...